Allspring Global Investments Holdings LLC Has $198,000 Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Allspring Global Investments Holdings LLC lowered its stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) by 6.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,378 shares of the company’s stock after selling 251 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Apogee Therapeutics were worth $198,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in APGE. EntryPoint Capital LLC raised its position in Apogee Therapeutics by 44.7% in the first quarter. EntryPoint Capital LLC now owns 1,997 shares of the company’s stock worth $133,000 after acquiring an additional 617 shares during the period. Kennedy Capital Management LLC purchased a new position in shares of Apogee Therapeutics during the 1st quarter valued at about $212,000. Arizona State Retirement System grew its holdings in shares of Apogee Therapeutics by 4.5% during the 2nd quarter. Arizona State Retirement System now owns 5,993 shares of the company’s stock valued at $236,000 after purchasing an additional 258 shares during the last quarter. Principal Financial Group Inc. grew its position in Apogee Therapeutics by 26.3% during the 2nd quarter. Principal Financial Group Inc. now owns 6,442 shares of the company’s stock worth $253,000 after acquiring an additional 1,340 shares during the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Apogee Therapeutics in the second quarter valued at about $272,000. 79.04% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Wedbush reaffirmed an “outperform” rating and issued a $87.00 target price on shares of Apogee Therapeutics in a research report on Friday, October 25th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Apogee Therapeutics presently has a consensus rating of “Buy” and an average target price of $78.50.

Insider Activity at Apogee Therapeutics

In other news, insider Carl Dambkowski sold 6,665 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $56.26, for a total transaction of $374,972.90. Following the sale, the insider now directly owns 274,128 shares in the company, valued at $15,422,441.28. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Apogee Therapeutics news, insider Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $56.26, for a total value of $374,972.90. Following the sale, the insider now directly owns 274,128 shares in the company, valued at approximately $15,422,441.28. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael Thomas Henderson sold 40,000 shares of the stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $40.62, for a total value of $1,624,800.00. Following the transaction, the chief executive officer now directly owns 1,434,487 shares of the company’s stock, valued at approximately $58,268,861.94. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 146,665 shares of company stock worth $7,058,635. Corporate insiders own 36.10% of the company’s stock.

Apogee Therapeutics Stock Performance

Shares of APGE stock opened at $54.49 on Monday. The company has a market capitalization of $2.45 billion, a price-to-earnings ratio of -26.32 and a beta of 2.94. The company’s 50-day moving average is $53.28 and its 200 day moving average is $48.45. Apogee Therapeutics, Inc. has a one year low of $14.19 and a one year high of $72.29.

Apogee Therapeutics (NASDAQ:APGE) last posted its earnings results on Monday, August 12th. The company reported ($0.60) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.60). As a group, research analysts predict that Apogee Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.